Table 1.

Comparative in vitro activity of eravacycline against selected Gram-positive clinical isolates

Pathogen	Total no. of isolates	MIC90 (μg/mL; range across studies) [% susceptible; CLSI or FDA/EUCAST]
		ERV [NA]	TGC	TZP	VAN
Aerobes
Enterococcus spp. [20]	406	0.06	1 [NR]
E. faecalis [16, 24, 25]	1605	0.06–0.12	0.25 [98.1–99.5/NR]	4 [NA/NR]	2 [NR]
E. faecalis (VR) [18, 24]	108	0.12	0.25 [NR]		> 32 to > 64 [NR]
E. faecalis (VS) [18]	121	0.12	0.25[98.1/NR]		2 [92.5/NR]
E. faecium [16, 24, 25]	1149	0.06	0.12–0.25 [93.2/NR]	>32 [NA/NR]	>32 [26.8/NR]
E. faecium (VR) [18, 24]	379	0.06	0.12–0.25 [NR]		> 32 to > 64 [NR]
E. faecium (VS) [18]	84	0.12	0.12 [NR]		1 [NR]
Staphylococcus aureus [20, 24]	2024	0.12	0.25 [NR]		1 [NR]
MRSA [16, 18, 20, 21, 24, 25]	2247	0.06–0.12	0.25–1 [97.7–98.4/NR]	128 [NA]	1 [100/NR]
MSSA [16, 18, 21, 25]	2006	0.06–0.25	0.25 [99.6–99.9/NR]	≤ 1 [NA]	1 [100/NR]
Streptococcus anginosus [18]	47	0.03	0.06 [NR]		1 [NR]
Streptococcus intermedius [18]	31	0.06	0.12 [NR]		0.5 [NR]
Streptococcus mitis [18]	62	0.12	0.12 [NR]		0.5 [NR]
Anaerobes
Clostridium perfringens [15]	15	1	2 [100/NA]	1 [100/100]	32 [NA/80]

Pathogens against which eravacycline has demonstrated efficacy in clinical trials [11, 13]. Studies involving >  500 clinical isolates collected in Canada (2014–2015 [16]), EU (2015 [21]), USA (2012–2015 [15]; 2013–2016 [25]; year(s) not stated [18]) or globally (2013–2015 [24]; year(s) not stated [20]); not all studies evaluated all drugs or reported susceptibility. Abstract presentations [20, 21, 24, 25]

CLSI Clinical and Laboratory Standards Institute, ERV eravacycline, EUCAST European Committee on Antimicrobial Susceptibility Testing, MIC₉₀ minimum inhibitory concentration required to inhibit 90% of isolates, MRSA methicillin-resistant S. aureus, MSSA methicillin-sensitive S. aureus, NA not applicable/no breakpoint, NR not reported, TGC tigecycline, TZP piperacillin/tazobactam, VAN vancomycin, VR VAN-resistant, VS VAN-sensitive